# reload+after+2024-01-22 11:43:19.734786
address1§One Amgen Center Drive
city§Thousand Oaks
state§CA
zip§91320-1799
country§United States
phone§805 447 1000
fax§805 447 1010
website§https://www.amgen.com
industry§Drug Manufacturers—General
sector§Healthcare
longBusinessSummary§Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
fullTimeEmployees§25200
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Robert A. Bradway', 'age': 60, 'title': 'Chairman, CEO & President', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 5487475, 'exercisedValue': 0, 'unexercisedValue': 43693576}, {'maxAge': 1, 'name': 'Mr. Peter H. Griffith', 'age': 64, 'title': 'Executive VP & CFO', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 2574004, 'exercisedValue': 0, 'unexercisedValue': 245771}, {'maxAge': 1, 'name': 'Mr. Esteban  Santos', 'age': 55, 'title': 'Executive Vice President of Operations', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 2521941, 'exercisedValue': 0, 'unexercisedValue': 8232750}, {'maxAge': 1, 'name': 'Dr. David M. Reese M.D.', 'age': 60, 'title': 'Executive VP & Chief Technology Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 2833393, 'exercisedValue': 0, 'unexercisedValue': 4932458}, {'maxAge': 1, 'name': 'Mr. Murdo  Gordon', 'age': 56, 'title': 'Executive VP of Global Commercial Operations', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 2717562, 'exercisedValue': 0, 'unexercisedValue': 2469817}, {'maxAge': 1, 'name': 'Mr. Matthew C. Busch', 'age': 49, 'title': 'Chief Accounting Officer & VP of Finance', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mike  Zahigian', 'title': 'Senior VP & Chief Information Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. James E. Bradner M.D.', 'age': 51, 'title': 'Executive VP of Research and Development & Chief Scientific Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Arvind  Sood', 'title': 'Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jonathan P. Graham', 'age': 62, 'title': 'Executive VP, General Counsel & Secretary', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 2440307, 'exercisedValue': 0, 'unexercisedValue': 2105468}]
auditRisk§2
boardRisk§8
compensationRisk§2
shareHolderRightsRisk§1
overallRisk§2
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
dividendRate§9.0
dividendYield§0.0297
exDividendDate§1707955200
payoutRatio§0.5925
fiveYearAvgDividendYield§2.96
beta§0.58
priceToSalesTrailing12Months§6.0432653
currency§USD
dateShortInterest§1702598400
forwardEps§20.07
pegRatio§3.09
exchange§NMS
quoteType§EQUITY
shortName§Amgen Inc.
longName§Amgen Inc.
firstTradeDateEpochUtc§424704600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§9376b97e-b428-3231-ba0b-142b20481cb4
gmtOffSetMilliseconds§-18000000
targetHighPrice§345.0
targetLowPrice§185.0
targetMeanPrice§285.09
targetMedianPrice§297.0
recommendationMean§2.3
recommendationKey§buy
numberOfAnalystOpinions§23
quickRatio§2.412
earningsGrowth§-0.191
grossMargins§0.73726
ebitdaMargins§0.4957
trailingPegRatio§2.1978
